Regeneron Sees Progress with Two Drug Candidates

Regeneron Pharmaceuticals Inc. said Wednesday early stage testing showed that one of its drug candidates lowered cholesterol levels, and mid-stage testing on a potential pain reliever showed it was well-tolerated, according to the Associated Press. The company said a cholesterol drug candidate labeled REGN727 achieved "substantial" decreases in low-density lipoprotein, or LDL, cholesterol at certain doses. It will present more information at its investor day July 15 in New York. Regeneron also said a pain reliever labeled REGN475 was "generally well tolerated" by patients. It showed improvements in walking pain when studied in 217 patients with osteoarthritis of the knee.